PMID- 36074263 OWN - NLM STAT- MEDLINE DCOM- 20230202 LR - 20230202 IS - 1432-1084 (Electronic) IS - 0938-7994 (Linking) VI - 33 IP - 2 DP - 2023 Feb TI - Mid-term efficacy grading evaluation and predictive factors of magnetic resonance-guided focused ultrasound surgery for painful bone metastases: a multi-center study. PG - 1465-1474 LID - 10.1007/s00330-022-09118-2 [doi] AB - OBJECTIVES: MR imaging-guided focused ultrasound surgery (MRgFUS) is an emerging non-invasive treatment. It is helpful in investigating the mid-term grading efficacy and safety of MRgFUS, and possible risk factors in participants with painful bone metastases. METHODS: This four-center prospective study enrolled 96 participants between June 2016 and May 2019 with painful bone metastases. The Numerical Rating Scale (NRS), Brief Pain Inventory-Quality of Life (BPI-QoL) score, morphine equivalent daily dose (MEDD), and the adverse events (AEs) were recorded before and at 1 week, 1 month, 2 months, and 3 months after MRgFUS. The repeated ANOVA tests were used to analyze the change in NRS and BPI-QoL, and logistic regression analysis was used to analyze the possible risk factors. RESULTS: A total of 82 participants completed the 3-month follow-up period. And 16 (19.5%) participants were complete responders (CR), 46 (56.1%) participants were effective responders (ER), and the other 20 (24.4%) participants were non-responders (NR). The NRS (2.67 +/- 2.47 at 3 months compared to 6.38 +/- 1.70 before treatment) and BPI-QoL score (3.11 +/- 2.51 at 3 months compared to 5.40 +/- 1.85 before treatment) significantly decreased after the treatment at all time points (p < 0.001). Eleven adverse events were recorded and they were all cured within 1 to 52 days after treatment. The non-perfused volume (NPV) ratio (p = 0.001) and the bone metastases lesion type (p = 0.025) were the key risk factors. CONCLUSIONS: MRgFUS can be used as a non-invasive, effective, and safe modality to treat painful bone metastases. NPV ratio and the lesion type may be used as affecting factors to predict the mid-term efficacy of MRgFUS. KEY POINTS: * MRgFUS can be considered a non-invasive, effective, and safe modality to treat painful bone metastases. * The NRS and BPI-QoL score at 1 week, 1 month, 2 months, and 3 months all decreased significantly (p < 0.001) after receiving MRgFUS. Among 82 participants, 16 (19.5%) were complete responders, 46 (56.1%) were effective responders, and the other 20 (24.4%) were non-responders. * According to logistic regression analysis, non-perfused volume ratio and the bone metastases lesion type were the affecting factors to predict the mid-term efficacy of MRgFUS. The adjusted OR of non-perfused volume ratio was 0.86 (p = 0.001), and osteoblastic lesion type was 0.06 (p = 0.025). CI - (c) 2022. The Author(s), under exclusive licence to European Society of Radiology. FAU - Yin, Xiaorui AU - Yin X AD - Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Tang, Na AU - Tang N AD - Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Fan, Xuhui AU - Fan X AD - Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Shengping AU - Wang S AD - Department of Radiology, Shanghai Cancer Center, Fudan University, Shanghai, China. FAU - Zhang, Junhai AU - Zhang J AD - Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China. FAU - Gu, Jianjun AU - Gu J AD - Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Han AU - Wang H AUID- ORCID: 0000-0001-8042-1232 AD - Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. han.wang@shsmu.edu.cn. LA - eng GR - 81871400/National Natural Science Foundation of China/ GR - 17XD1424200/Shanghai Municipal Science and Technology Commission/ GR - 18441905000/Shanghai Municipal Science and Technology Commission/ GR - SHDC2017127/Shanghai Hospital Development Center/ GR - 20152230/Gaofeng Clinical Medicine Grant of Shanghai Municipal Education Commission/ PT - Journal Article PT - Multicenter Study DEP - 20220908 PL - Germany TA - Eur Radiol JT - European radiology JID - 9114774 SB - IM MH - Humans MH - Quality of Life MH - Pain Management MH - Prospective Studies MH - Pain/etiology MH - Magnetic Resonance Imaging MH - *Bone Neoplasms/diagnostic imaging/surgery MH - *High-Intensity Focused Ultrasound Ablation/adverse effects MH - Magnetic Resonance Spectroscopy MH - *Ultrasonic Surgical Procedures MH - Treatment Outcome OTO - NOTNLM OT - MR imaging-guided focused ultrasound surgery OT - Mid-term efficacy grading OT - Pain palliation OT - Painful bone metastases OT - Risk factors EDAT- 2022/09/09 06:00 MHDA- 2023/02/03 06:00 CRDT- 2022/09/08 11:18 PHST- 2022/04/02 00:00 [received] PHST- 2022/08/17 00:00 [accepted] PHST- 2022/07/04 00:00 [revised] PHST- 2022/09/09 06:00 [pubmed] PHST- 2023/02/03 06:00 [medline] PHST- 2022/09/08 11:18 [entrez] AID - 10.1007/s00330-022-09118-2 [pii] AID - 10.1007/s00330-022-09118-2 [doi] PST - ppublish SO - Eur Radiol. 2023 Feb;33(2):1465-1474. doi: 10.1007/s00330-022-09118-2. Epub 2022 Sep 8.